Literature DB >> 8019773

Antidepressant-like effects of CCKB antagonists in mice: antagonism by naltrindole.

M Derrien1, C Durieux, B P Roques.   

Abstract

1. The effects of selective CCKB agonists, BC 264 and BC 197 were investigated in the conditioned suppression of motility test in mice, an animal model used to select antidepressant drugs. The results showed that both CCKB agonists at doses of 3 and 30 micrograms kg-1, accentuated the suppression of motility in shocked mice and did not modify the behaviour of non-shocked mice. The effects of BC 264 were suppressed by L-365,260. 2. L-365,260 alone, at doses of 0.2 and 2 mg kg-1 decreased motor inhibition in shocked mice and had no effect in non-shocked mice. 3. The effects of L-365,260 observed in shocked mice were suppressed by naltrindole, a selective antagonist for delta-opioid receptors, suggesting the occurrence of physiological adverse interactions between CCK and opioid systems. 4. Together, these results suggest that CCKB antagonists could block centrally located CCKB receptors to produce antidepressant-like effects which could indirectly involve delta-opioid receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8019773      PMCID: PMC1910081          DOI: 10.1111/j.1476-5381.1994.tb14832.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

1.  Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.

Authors:  J Bradwejn; D Koszycki; C Shriqui
Journal:  Arch Gen Psychiatry       Date:  1991-07

2.  CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects.

Authors:  R B Lydiard; J C Ballenger; M T Laraia; M D Fossey; M C Beinfeld
Journal:  Am J Psychiatry       Date:  1992-05       Impact factor: 18.112

3.  Lesion of dopamine mesolimbic neurons blocks behavioral effects induced by the endogenous enkephalins but not by a mu-opioid receptor agonist.

Authors:  G Calenco-Choukroun; V Daugé; G Gacel; B P Roques
Journal:  Eur J Pharmacol       Date:  1991-12-17       Impact factor: 4.432

4.  Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260.

Authors:  M F O'Neill; C T Dourish; S D Iversen
Journal:  Eur J Pharmacol       Date:  1991-02-07       Impact factor: 4.432

5.  Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat.

Authors:  J Harro; E Vasar
Journal:  Eur J Pharmacol       Date:  1991-02-14       Impact factor: 4.432

6.  Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCKB receptors by using a new highly potent CCK analog, BC 264.

Authors:  V Dauge; G A Bohme; J N Crawley; C Durieux; J M Stutzmann; J Feger; J C Blanchard; B P Roques
Journal:  Synapse       Date:  1990       Impact factor: 2.562

7.  The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260, enhance morphine antinociception only in non-acclimated rats exposed to a novel environment.

Authors:  G J Lavigne; W R Millington; G P Mueller
Journal:  Neuropeptides       Date:  1992-02       Impact factor: 3.286

8.  PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes.

Authors:  Z Wiesenfeld-Hallin; X J Xu; J Hughes; D C Horwell; T Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 9.  Validation criteria for panic disorder as a nosological entity.

Authors:  R Rosenberg; J O Ottosson; P Bech; M Mellergård; N K Rosenberg
Journal:  Acta Psychiatr Scand Suppl       Date:  1991

10.  Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.

Authors:  L Singh; A S Lewis; M J Field; J Hughes; G N Woodruff
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

View more
  9 in total

1.  cDNA microarray analysis of gene expression in the cerebral cortex and hippocampus of BALB/c mice subjected to chronic mild stress.

Authors:  Yanyong Liu; Nan Yang; Pingping Zuo
Journal:  Cell Mol Neurobiol       Date:  2010-06-09       Impact factor: 5.046

2.  The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats.

Authors:  O Valverde; M C Fournie-Zaluski; B P Roques; R Maldonado
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

3.  Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects.

Authors:  C Smadja; R Maldonado; S Turcaud; M C Fournie-Zaluski; B P Roques
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

Review 4.  Association of enkephalin catabolism inhibitors and CCK-B antagonists: a potential use in the management of pain and opioid addiction.

Authors:  B P Roques; F Noble
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

5.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

6.  Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats.

Authors:  D Charrier; L Dangoumau; A J Puech; M Hamon; M H Thiébot
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

7.  Impairment of stress adaptive behaviours in rats by the CCKA receptor antagonist, devazepide.

Authors:  F Hernando; J A Fuentes; M Ruiz-Gayo
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

8.  Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308.

Authors:  R Maldonado; O Valverde; B Ducos; A G Blommaert; M C Fournie-Zaluski; B P Roques
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

Review 9.  Novel Molecular Targets of Antidepressants.

Authors:  Małgorzata Jarończyk; Jarosław Walory
Journal:  Molecules       Date:  2022-01-14       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.